STING

News
Mersana stung by FDA hold on STING drug

Mersana stung by FDA hold on STING drug

A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug conjugate XMT-2056 has resulted in the FDA formally placing the study on clinical hold.<

Events
pharmaphorum
Partner Content

STING & TLR Targeting Therapies Summit

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as